ClinicalTrials.gov
ClinicalTrials.gov Menu

A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00887484
Recruitment Status : Completed
First Posted : April 24, 2009
Results First Posted : October 23, 2012
Last Update Posted : December 13, 2016
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
GlaxoSmithKline ( Stiefel, a GSK Company )

April 23, 2009
April 24, 2009
September 22, 2010
October 23, 2012
December 13, 2016
February 2009
June 2009   (Final data collection date for primary outcome measure)
  • Erythema (Redness) [ Time Frame: Weeks 1 and 2 ]
    Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
  • Skin Dryness [ Time Frame: Weeks 1 and 2 ]
    Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
  • Skin Peeling [ Time Frame: Weeks 1 and 2 ]
    Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3,Intense.
  • Irritant/Allergic Contact Dermatitis [ Time Frame: Weeks 1 and 2 ]
    Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis) [ Time Frame: 2 weeks ]
Complete list of historical versions of study NCT00887484 on ClinicalTrials.gov Archive Site
  • Erythema (Redness) [ Time Frame: Weeks 5 and 8 ]
    Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
  • Skin Dryness [ Time Frame: Weeks 5 and 8 ]
    Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
  • Skin Peeling [ Time Frame: Weeks 5 and 8 ]
    Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
  • Irritant/Allergic Contact Dermatitis [ Time Frame: Weeks 5 and 8 ]
    Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.
  • Investigators Static Global Assessment [ Time Frame: Baseline, Weeks 5, 8 ]
    ISGA is evaluated using the following scale: 0, Clear: Clear skin with no lesions; 1, Almost Clear: Rare non-inflammatory lesions; 2, Mild: Some non-inflammatory lesions with no more than a few inflammatory lesions but no nodular lesions); 3, Moderate: Up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than 1 small nodular lesion; 4, Severe: Up to many non-inflammatory and inflammatory lesions, but no more than a few nodular lesions; 5, Very Severe: Many non-inflammatory and inflammatory lesions and more than a few nodular lesions. May have cystic lesions.
  • Total Acne Lesion Counts [ Time Frame: Baseline, Weeks 5 and 8 ]
    Total acne lesion counts - includes both inflammatory acne lesions (pustules, papules), noninflammatory lesions (whiteheads and blackheads),
  • Inflammatory Acne Lesion Counts [ Time Frame: Baseline, Weeks 5 and 8 ]
    Total number of inflammatory acne lesions (pustules, papules) at each timepoint.
  • Non-inflammatory Acne Lesion Counts [ Time Frame: Baseline, Weeks 5 and 8 ]
    Total number of non-inflammatory acne lesions (whiteheads and blackheads) at each timepoint.
  • Skindex-29 Quality of Life Questionnaire (QoL) - Symptomatic Domain [ Time Frame: Baseline, Weeks 2 and 8 ]
    Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The symptomatic score (score=0 to 28)=(sum of the 7 individual item scores) * 100/28.
  • Quality of Life Questionnaire - Emotional Domain [ Time Frame: Baseline, Weeks 2 and 8 ]
    Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The emotional score (score=0 to 40)=(sum of the 10 individual item scores) * 100/40.
  • Quality of Life Questionnaire - Functional Domain [ Time Frame: Baseline, Weeks 2 and 8 ]
    Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The functional score (score=0 to 48)=(sum of the 12 individual item scores) * 100/48.
  • Quality of Life Questionnaire - Global Score [ Time Frame: Baseline, Weeks 2 and 8 ]
    Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. A Global Score (range 0-100)=(sum of all 29 individual item scores) * 100/116.
  • Product Acceptability and Preference Questionnaire - Severity of Redness at Weeks 1 and 2 [ Time Frame: Weeks 1 and 2 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
  • Product Acceptability and Preference Questionnaire - Severity of Redness at Week 8 [ Time Frame: Week 8 ]
    Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
  • Product Acceptability and Preference Questionnaire - Severity of Dryness at Weeks 1 and 2 [ Time Frame: Weeks 1 and 2 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
  • Product Acceptability and Preference Questionnaire - Severity of Dryness at Week 8 [ Time Frame: Week 8 ]
    Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
  • Product Acceptability and Preference Questionnaire - Severity of Burning at Weeks 1 and 2 [ Time Frame: Weeks 1 and 2 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
  • Product Acceptability and Preference Questionnaire - Severity of Burning at Week 8 [ Time Frame: Week 8 ]
    Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
  • Product Acceptability and Preference Questionnaire - Severity of Itching at Weeks 1 and 2 [ Time Frame: Weeks 1 and 2 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
  • Product Acceptability and Preference Questionnaire - Severity of Itching at Week 8 [ Time Frame: Week 8 ]
    Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.
  • Product Acceptability and Preference Questionnaire - Severity of Scaling at Weeks 1 and 2 [ Time Frame: Weeks 1 and 2 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.
  • Product Acceptability and Preference Questionnaire - Severity of Scaling at Week 8 [ Time Frame: Week 8 ]
    Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.
  • Product Acceptability and Preference Questionnaire - Ease of Application of Product at Weeks 1 and 2 [ Time Frame: Weeks 1 and 2 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.
  • Product Acceptability and Preference Questionnaire - Ease of Application of Product at Week 8 [ Time Frame: Week 8 ]
    Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.
  • Product Acceptability and Preference Questionnaire - Comfort of Skin at Weeks 1 and 2 [ Time Frame: Weeks 1 and 2 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.
  • Product Acceptability and Preference Questionnaire - Comfort of Skin at Week 8 [ Time Frame: Week 8 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.
  • Product Acceptability and Preference Questionnaire - Which Study Product is Subject More Satisfied With? at Weeks 1 and 2 [ Time Frame: Weeks 1 and 2 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following choices: Epiduo, Clindoxyl Gel, Both Treatments Equally.
  • Product Acceptability and Preference Questionnaire - Comparison of Study Products Used in the Past at Week 8 [ Time Frame: Week 8 ]
    Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, More Satisfied; 2, Somewhat More Satisfied; 3, Neither Satisfied or Dissatisfied; 4, Somewhat More Dissatisfied; 5, More Dissatisfied.
  • Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Weeks 1 and 2 [ Time Frame: Weeks 1 and 2 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, Uncomfortable.
  • Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Week 8 [ Time Frame: Week 8 ]
    Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, More Dissatisfied.
  • Product Acceptability and Preference Questionnaire - Compliance at Weeks 1 and 2 [ Time Frame: Weeks 1 and 2 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Compliant at all; 1, Mostly Compliant; 2, Very Compliant.
  • Product Acceptability and Preference Questionnaire - Compliance at Week 8 [ Time Frame: Week 8 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at week 8 by answering Yes or No to the following question: Did you use the product every day?. When only one product was applied to the face, subjects were asked to rate their compliance by answering the aforementioned question, rather than rating compliance on a 0-2 scale.
  • Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Weeks 1 and 2 [ Time Frame: Weeks 1 and 2 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?
  • Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Week 8 [ Time Frame: Week 8 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?
  • Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 1 and 2 [ Time Frame: Weeks 1 and 2 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?
  • Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 8 [ Time Frame: Week 8 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at 8 week timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?
  • Product Acceptability and Preference Questionnaire - Ease of Use Wtih Make-Up at Weeks 1 and 2 [ Time Frame: Weeks 1 and 2 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.
  • Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up at Week 8 [ Time Frame: Week 8 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.
  • Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Weeks 1 and 2 [ Time Frame: Weeks 1 and 2 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.
  • Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Week 8 [ Time Frame: Week 8 ]
    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.
Efficacy parameters ISGA, lesion counts, and Subject Global Change Assessment at each visit will be assessed, quality of life (SKINDEX-29) and product acceptability [ Time Frame: 8 weeks ]
Not Provided
Not Provided
 
A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne
A Single-blind, Randomized, Comparative Pilot Study Evaluating the Tolerability of Two Topical Combination Therapies in the Treatment of Acne Vulgaris
The purpose of this study is to compare the tolerability of topical combination therapies in the treatment of facial acne.
The purpose of this study is to compare the tolerability of topical combination therapies in the treatment of facial acne.
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Acne Vulgaris
  • Drug: BENZOYL PEROXIDE/ CLINDAMYCIN
    Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
  • Drug: BENZOYL PEROXIDE/ ADAPALENE
    Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
  • Experimental: Clindoxyl Gel
    Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.
    Intervention: Drug: BENZOYL PEROXIDE/ CLINDAMYCIN
  • Active Comparator: Epiduo gel
    Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.
    Intervention: Drug: BENZOYL PEROXIDE/ ADAPALENE
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
45
June 2009
June 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female subjects at least 21 years of age, in good general health with documented diagnosis of acne vulgaris.
  • Female subjects of childbearing potential must have a negative pregnancy test. Sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception Abstinence is considered an acceptable method of contraception.
  • Inflammatory (papules and pustules) and non-inflammatory (open and closed comedones) facial lesions.
  • The ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study
  • Capable of understanding and willing to provide signed and dated written voluntary informed consent (and any local or national authorization requirements) before any protocol specific procedures are performed

Exclusion Criteria:

  • Female subjects who are pregnant, trying to become pregnant or breastfeeding.
  • Subjects who have any clinically relevant finding at their baseline physical other than acne vulgaris.
  • History or presence of regional enteritis or inflammatory bowel disease (eg, ulcerative colitis, pseudomembranous colitis, chronic diarrhea, or a history of antibiotic-associated colitis) or similar symptoms.
  • Use of topical antibiotics or anti-acne medications on the face and systemic antibiotics within the past 2 and 4 weeks, respectively.
  • Use of topical corticosteroids on the face or systemic corticosteroids within the past 4 weeks. Use of inhaled, intra-articular or intra-lesional (other than for facial acne lesions) steroids is acceptable.
  • Use of systemic retinoids within the past 6 months.
  • Facial procedures performed by an esthetician, beautician, physician, nurse, or other practitioner, within the past 4 weeks or during the conduct of the study.
  • Known hypersensitivity or previous allergic reaction to any of the active components, lincomycin, adapalene, clindamycin, benzoyl peroxide or excipients of the study product.
Sexes Eligible for Study: All
21 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Argentina
 
 
NCT00887484
114544
No
Not Provided
Plan to Share IPD: Yes
Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
GlaxoSmithKline ( Stiefel, a GSK Company )
Stiefel, a GSK Company
GlaxoSmithKline
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
October 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP